ACTR-95. HYPOXIA ACTIVATED EVOPHOSPHAMIDE (TH-302) FOR RECURRENT GBM FOLLOWING BEVACIZUMAB FAILURE, A MULTICENTER PHASE II STUDY

INTRODUCTION: TH-302 (evophosphamide) is a hypoxia-activated prodrug that, when activated in hypoxic conditions (<0.5% O2), releases the bis-alkylating agent bromo-isophosphoramide mustard (Br-IPM), which can then act as a DNA crosslinking agent. In vivo, TH-302 has shown to potentiate the anti-t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Brenner, Andrew, Reardon, David, Wen, Patrick, Fox, Peter, Huang, Shiliang, Muzi, Mark, Liu, Yichu, Lee, Eudocia
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2017
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692401/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.079
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars